Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
By K. Metcalfe, H. Lynch, P. Ghadirian, N. Tung, I. Olivotto, E. Warner, O. Olopade, A. Eisen, Barbara L. Weber, Jane McLennan and 3 more. Journal of Clinical Oncology, 2004
644 citations recorded by the source corpus.
Subfields: Cancer Research, Genetics, Public Health, Environmental and Occupational Health
View Paper: https://www.semanticscholar.org/paper/6334c5843be9ad24ea33d52915f0df628fa4cafd
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
Citations in the corpus
- Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. (2005, background): “Secondary prevention (ie, intensified surveillance) is recommended rather than preventive mastectomy for so-far healthy women and, because of the high risk of second primaries, also for women who already developed breast cancer.(11) Current guidelines recommend screening by clinical breast examinati”
- Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. (2010, background): “This risk is reduced after bilateral oophorectomy or treatment with tamoxifen.(103) The high probability of a second breast cancer for high-risk women poses the rationale for including these women in surveillance programmes with MRI.”
- Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers with Cancer Risk and Mortality (2010, neutral): “Regardless of the effect of oophorectomy on second diagnosis of breast cancer, oophorectomy is essential to reduce the risk of ovarian cancer, which can be a significant cause of morbidity and mortality in women with earlystage breast cancer.(29) Our data suggest that risk-reducing salpingo-oophorec”